Men's Health

This article discusses the risk of depression and suicide in men, focusing on increased risk in men with genitourinary cancer and other urologic conditions.

To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.

A 25-year-old male presents with 4 weeks of intermittent right flank pain occasionally radiating to the testicle. CT shows a 7-cm partially necrotic retroperitoneal mass at the level of the right renal vein and a 2-cm lesion overlaying the right psoas muscle.

Imaging reveals a mass at the anterior bladder dome with inflammation extending to the perivesical fat. No pelvic lymphadenopathy or sites of metastatic disease are found.

"As much as racial and ethnic disparities exist broadly across health care in the United States, it is not surprising to observe this phenomenon in the urologic arena," writes Arthur L. Burnett, II, MD, MBA.

In this article, we describe our thought processes in treating patients with Peyronie's disease, which are summarized in an algorithm.

There are no national or international guidelines regarding penile transplants, raising a question without a concrete answer: What are the rules and the limits?

"[Penile transplantation] is a real advance for patients who have a penile deficiency or penile loss," says Arthur L. Burnett, II, MD, MBA.

These videos depict key steps of office-based approaches to hydrocelectomy and vasectomy reversal.

"There are direct endocrine consequences of opioid use, including hypogonadism, that adversely impact men’s health," write Michael S. Leapman, MD, and Steven A. Kaplan, MD.

The overall use of active surveillance in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.

Tissue-based prognostic biomarker assays for prostate cancer are not robust to tumor multifocality and heterogeneity, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.

Other pipeline products discussed in this round-up include and advanced renal cell carcinoma agent, a bladder cancer detection agent, and a BPH treatment.

It’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising.

Other products and services discussed in this round-up include a biosimilar for cancer, an American College of Surgeons manual on quality initiatives, a kidney cancer microsite, and more.

Adherence to current guidelines for genetic testing in men with prostate cancer would miss a sizable proportion of patients with pathogenic germline variants, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.

Treatment with radiotherapy plus androgen deprivation therapy may improve survival for select patients who are found to have pathologic node-positive prostate cancer at radical prostatectomy

This article presents an overview of the pathophysiology of varicoceles and discusses indications for treatment, two primary repair techniques, and treatment outcomes.

Heat-free high-velocity waterjet ablation (Aquablation) for BPH performed with an image-guided robot-assisted platform (AquaBeam System) met its primary safety and efficacy endpoints in a phase III study.

Treatment of lower urinary tract symptoms/BPH with convective water vapor ablation (Rezum System) appears to provide significant improvement on two key outcome measures versus medical therapy at up to 2 years, according to a study presented at the AUA annual meeting in Boston.

Information from magnetic resonance imaging and systematic biopsy may be used to identify candidates for partial gland ablation among men with recurrent localized prostate cancer after radiation therapy, researchers from Memorial Sloan Kettering Cancer Center reported at the AUA annual meeting in Boston.

The risk of erectile dysfunction is not increased with the use of a 5-alpha-reductase inhibitor compared with an alpha-blocker for the treatment of BPH.

Early follow-up of men with localized prostate cancer treated with novel technology that integrates fusion biopsy findings to guide high-intensity focused ultrasound (HIFU [Focal One]) shows the technique has promise for minimizing post-treatment morbidity while providing good cancer control, Italian researchers reported at the AUA annual meeting in Boston.